Introduction
Malignant lymphomas frequently develop in the pleural cavity of patients with longstanding pyothorax. 1, 2 Thus, the term pyothorax-associated lymphoma (PAL) has been proposed for these tumors. Most PALs are diffuse large cell lymphomas (DLCL) of B cell type, 1,2 contain Epstein-Barr virus (EBV) DNA, 3, 4 and express some EBV latent infection genes, EBV nuclear antigen 2 (EBNA2) and latent membrane protein 1 (LMP1). [3] [4] [5] EBV is identified as an etiological agent of African type of Burkitt's lymphoma and nasopharyngeal carcinoma in southern China. 6 Latent infection genes of EBV including EBNAs and LMPs are expressed in latently infected and immortalized B cells. 7 EBV infection such as acquired immunodeficiency syndrome in immunocompromised patients or allograft recipients receiving immunosuppressive therapy evoke polyclonal B cell proliferative disorders, frequently resulting in monoclonal malignant lymphomas. 8, 9 These lymphomas are most often diffuse lymphomas of B cell type and exhibit EBV DNA. 8, 9 The clonality of B cell lymphoma is determined primarily by the rearrangement pattern of immunoglobulin (Ig) genes and sometimes by that of some oncogenes. 10 Circularization of the EBV genome produces EBV episomes that have variable numbers of terminal repeats (TRs) that differ between individual clones, and the presence of a single predominant band containing TR represents the clonal cellular proliferation of Correspondence: K Aozasa, Department of Pathology, Osaka University Medical School, 2-2 Yamada-oka, Suita 565-0871, Japan Received 10 April 1997; accepted 31 March 1998 EBV-infected progenitor cells. 11 Thus, TR of EBV is also used as a clonal marker of EBV-positive lymphomas. Furthermore, EBV also infects pre-B cells which show germ line configuration of Ig genes 12 and many cases of EBV-positive B cell lymphoma are reported to be monoclonal at the level of the EBV genome without clonal rearrangement of the Ig gene. 13, 14 Therefore, the TR of EBV genome is a more stable clonal marker of EBV-positive B cell neoplasms than Ig gene rearrangements.
The analysis of clonality is important in B cell proliferative disorders not only in the diagnosis of neoplasm but also in the analysis of etiopathogenesis of the disease. Lymphomas in immunosuppressive conditions start as polyclonal B cell proliferation and finally develop into oligo-or monoconal lymphomas whereas lymphomas developed in non-immunocompromised patients show a monoclonal nature even at the initial stage of the disease. 15 In phenotypes including EBV gene expression, PAL resembles lymphomas developing in immunocompromised patients. 5 Both lymphomas express EBNA2, which is not expressed in other EBV-positive neoplasms including Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma, and some T-or NK/T cell lymphomas.
6,7 EBNA2 works as a target antigen for host immune reactions to EBV. 7 In this context, systemic immunosuppressive conditions have not been noted in PAL cases although local immunosuppressive conditions may be involved in the development of PAL. 16 In this study, we describe a PAL case in which lymphoma recurred 19 months after complete remission (CR). The EBV clone in the recurrent tumor was different from that in the primary one. The role of EBV in the development of PAL is discussed.
Case report
A 76-year-old Japanese man presented in June 1993 with chest pain that had arisen during the previous 2 months. He had a 46 year history of pyothorax due to pulmonary tuberculosis. Physical examination of the right thoracic wall showed a hard mass, approximately 6 × 5 cm in size and poor in mobility. Superficial lymph nodes were not palpable and hepatosplenomegaly was not observed. Laboratory examinations revealed a slight elevation of lactate dehydrogenase (493 IU/l). The peripheral blood picture showed red blood cells 498 × 10 4 /l, platelets 21.9 × 10 4 /l, and white blood cells 6.2 × 10 3 /l with normal differential counts. Hemoglobin was 15.6 g/dl. EBV-related antibody titers were anti-viral capsid antigens 640 × (IgG), Ͻ10 × (IgM), Ͻ10 × (IgA); anti-early antigens Ͻ10 × (IgG), Ͻ10 × (IgA); and anti-EBNA 20 x. Chest X-ray showed a thickening of the right pleural wall. An open surgical biopsy was performed and histopathologic examination revealed diffuse large cell lymphoma (DLCL). At that time small pieces of biopsy specimens were cultured in vitro and a PAL cell line, OPL-1, was established. 5 After antineoplastic chemotherapy including cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP), he entered into CR. However, in May 1995, a tumor developed again near the site of the primary tumor. An open biopsy was performed and the recurrent tumor was also diagnosed as DLCL. Antineoplastic chemotherapy (CHOP) was not effective, and high fever and leukocytopenia were observed. His general condition deteriorated and he died in August 1995. An autopsy was performed.
Materials and methods

Cells
A PAL cell line, OPL-1, 5 was grown in RPMI 1640 medium (Nissui, Tokyo, Japan) supplemented with 15% heat-inactivated fetal calf serum (FCS; Whittaker, Walkersville, MD, USA). EBV-positive and -negative Burkitt's lymphoma cell lines, Raji and Ramos, respectively, and T cell line, MOTL4, were obtained from the Japanese Cancer Research Resources Bank (JCRRB). EBV-negative Burkitt's lymphoma cell line, BJAB, and EBV-producing marmoset cell line, B95-8, were kindly provided by Prof Kenzo Takada (Hokkaido University, Sapporo, Japan). A human T cell line, Jurkat, was donated by Prof Masato Nose (Ehime University, Shigenobu, Japan). These cell lines were grown in RPMI 1640 supplemented with 10% heat-inactivated FCS. The cells were collected at the density of 5 × 10 5 cells/ml and used for DNA extraction.
Immunophenotypic analysis
Three micrometer sections of formalin-fixed, paraffin-embedded tissue were subjected to immunochemistry for the examination of expression of cell surface marker proteins and EBV latent infection gene products as previously described. 4 The polyclonal antisera and the monoclonal antibodies used in this study, together with their respective clusters of differentiation and EBV antigens, are shown in Table 1 .
In situ hybridization
Three micrometer sections of formalin-fixed, paraffin-embedded tissue were subjected to in situ hybridization analysis for EBER-1 RNA. EBER-1 oligonucleotide probe was labeled with digoxygenin and signals were developed with alkaline phosphatase-labeled anti-digoxygenin antibodies as previously described. 17 Sections treated with RNase before hybridization or probed with sense-oligonucleotide probe were used as negative controls for hybridization.
DNA extraction and southern blot analysis
Total cellular DNA was extracted from cells or frozen tissue specimens as described previously. 18 DNA was quantitated by measuring OD 260 and stored at −20°C until use. Extracted DNA was digested with BamHI or with HindIII (GIBCO-BRL, Gaithersburg, MD, USA), electrophoresed in agarose gels, and Southern blotted as described previously. CAATGC-3′, in exon 2) 19 or with LMP2 oligonucleotide probe (5′-TGTAAGAATCCAGGCAGACAAAAGCGTGTT-3′, in exon 7) 20 as previously described 5 with the exception of additional washing at 60°C for 20 min. LMP1 exon 2 and LMP2 exon 7 are located in the BamHI-NJ het fused terminal fragment, which include about 500 bp TR of EBV, 19, 20 and are also located in right and left ends of the genome, respectively. Since reduplication of TR is variable among EBV clone, the presence of a single predominant band of BamHI-NJ het fragment represents clonal proliferation of EBV-infected cells. 11 For examination of clonality of the immunoglobulin gene, the filters with HindIII-digested DNAs were hybridized with human immunoglobulin J H probe, 21 which was obtained from JCRRB, as previously described. 5 
PCR amplification of the EBNA2 gene and southern blot analysis for the typing of the EBV Genome
For the PCR amplification of the EBNA2 region of the EBV genome, primers are designed to amplify the 89 bp segment, both ends of which are conserved with the middle portion varying between type A and B EBV. 22, 23 Primer sequences were 5′-CCACCAGCAGCACCAGCACA-3′ and 5′-GGTGGCCACCATGGTGGCCC-3′. 23 PCR was performed, and amplified products were electrophoresed in 2% agarose gels, and Southern blotted as previously described.
18 EBN-A2A-or 2B-specific oligonucleotide probes (EBNA2A-specific, 5′-TTACATCATCTACCCTCG-3′; EBNA2B-specific, 5′-GCACTTCCTCCAACTCCA-3′) were designed to hybridize to the variable region between the two primers 23 and 3′-end labeled with fluorescein-11-dUTP by using ECL 3′-oligolabeling system (Amersham, Buckinghamshire, UK). Filters were hybridized with the labeled probe, washed, and signals were generated as previously described.
Results
Pathologic characteristics of lymphoma
The primary and recurrent tumors showed almost the same characteristics (Figure 1a and b) : the lymphoma cells had abundant, occasionally basophilic cytoplasm and large vesicular nuclei with a prominent nucleoli. Mitotic figures were numerous. Tingible body macrophages with nuclear debris were sprinkled in the tumor. From these findings, histologic diagnosis of DLCL, immunoblastic type, was made.
Autopsy results
There was a necrotic and fragile tumor covering the surface of the right lung. The tumor invaded into the parenchyma of the right lung and chest wall (Figure 2 ). Other organs involved were the spleen and diaphragm which are exposed to the abdominal cavity. In the descending colon, there was a tumor with Borrmann II appearance. Histology was adenocarcinoma.
Immunophenotypic results
Immunophenotypes of tumor cells in both specimens are summarized in Table 1 . Although there was a little variation in positive reaction to some B cell marker antibodies, lymphoma cells in both specimens exhibited B cell characteristics.
Expression of EBV latent antigens and EBV RNA
Approximately one-third and one-fifth of tumor cells in biopsy specimens of primary and recurrent tumor, respectively, were positive for EBNA2 (Figure 1c and d) . On the other hand, reactivity for LMP1 was weak and found only in a small number of tumor cells in both specimens. LMP1-positive lymphoma cells were a little more frequent in the recurrent tumor than in the primary one (Figure 1e and f) .
In situ hybridization for EBER-1 RNAs revealed that approximately one half of tumor cells in both specimens contained EBV transcripts (Figure 1g and h) . Neither RNase treatment before hybridization nor hybridization with sense-probe generated signals (results not shown). These results clearly indicate that tumor cells in both specimens were latently infected with EBV.
Clonality analyses
In Southern blot analysis of BamHI-digested DNA samples probed with LMP1 oligonucleotide probe, both tissues contained a monoclonal terminal repeat in fused form (Figure 3a) . We could not analyze the same filter because the DNA samples extracted from the primary biopsy specimen were used up before performing the Southern blot of DNA samples from the recurrent tumor. Thus, we used the DNA samples extracted from the OPL-1, which is the cell line established from the primary biopsy specimen and contains the episomal EBV DNA with the same size of TR in fused form as that in primary biopsy tissue, 5 as a reference DNA sample for the evaluation of the EBV clone in the recurrent tumor. The size of BamHI-NJ het fragments was different between the primary and the recurrent tumor, ie approximately 8 kb in primary tissue and 15 kb in the recurrent one (Figure 3a) . Thus, the lymphoma cells in the primary tumor biopsy and recurrent tumor contained monoclonal EBV, however, the clone of EBV in the recurrent tumor was different from that in the primary tumor. The Southern blot analysis probed with LMP2 oligonucleotide probe, which hybridizes the left end of the genome, resulted in the same bands as those in the Southern analysis probed with LMP1 oligonucleotide probe (results not shown).
Although no clear band in Southern blot analyses with J H probe has been observed in OPL-1 and in the primary tumor as previously described, 5 we performed the same analyses for the rearrangements of IgH gene in the recurrent tumor. After digestion with HindIII, the recurrent tumor clearly displayed clonal rearrangements of the IgH gene (Figure 3b) . Thus, the recurrent tumor was probably different from the primary one also in the configuration of IgH rearrangements.
The subtype of EBV in both the primary and recurrent tumor was type B by the PCR-Southern blot analysis (Figure 3c ). Thus, both tumors contained the same type of EBV, but the clones contained were different.
Discussion
In 1987, we reported three patients who developed pleural lymphoma after a 22-30 year history of pyothorax resulting from artificial pneumothorax for the treatment of pulmonary tuberculosis or tuberculous pleuritis. 1 These cases were found among 134 patients with chronic pyothorax (CP) at one of the hospitals specializing in chest diseases in Osaka, Japan, during the period 1971-1985. We regarded the CP to be etiologically important in the development of pleural lymphoma because: (1) no occurrence of pleural lymphoma was found in over 2000 cases of malignant lymphoma admitted to the general hospitals in Osaka; (2) all six cases of pleural lymphoma registered in the 'Annual of the Pathological Autopsy Cases in Japan (1974-85)' were associated with CP; and (3) all cases of pleural lymphoma reported in the Japanese journals on chest diseases were associated with CP. The development of pleural lymphoma in CP suggests that chronic inflammatory stimulation can be an etiologic factor in the development of malignant lymphoma. To confirm this and obtain more detailed information on pleural lymphomas, we carried out a nation-wide study in Japan during 1987-1988. 2 The clinical information in 37 patients with pleural lymphoma in Japan indicates that the age at first diagnosis of lymphoma was 46-81 years (mean, 63); the male:female ratio was 5.2:1. All patients were admitted to the hospital with a Ͼ20 year history of CP resulting from artificial pneumothorax for the treatment of pulmonary tuberculosis or tuberculous pleuritis. Common presenting symptoms were pain in the chest, back or shoulder, and respiratory symptoms such as productive cough, often with hemoptysis, fever or dyspnea. Five patients presented with a tumor of the chest wall. Chest X-ray films and computed tomographic (CT) scans revealed masses in 13 (35%) of 37 patients and 24 (77%) of 31 patients, respectively. The main masses detected by these investigations were situated in the pleura (28 patients), the lung near the pleura (five patients), and the pleura and lung (four patients). Combined findings from the physical examination, X-ray films, CT and echogram revealed direct invasion to adjacent structures, such as the chest wall, lung, pericardium and diaphragm, in 21 of 37 patients. Six patients had regional and nine had distant nodal enlargement. No patient had a leukemic blood picture. 
Figure 2
Resected right lung at autopsy. Cut surface of the lung shows that a necrotic tumor covers the surface of the lung, partly invading the parenchyma.
As for the pathologic findings of these cases, the pleural tissue adjoining the tumors generally showed marked fibrous thickening, with sparse non-neoplastic inflammatory cells mainly comprising small lymphocytes and plasma cells. All cases were non-Hodgkin's lymphomas with approximately 80% being of the diffuse large cell type. Immunohistochemical studies revealed that all cases but one were of B cell lineage. Autopsies showed that the malignant lymphomas were localized in the thoracic cavity in approximately half of the cases. Extrathoracic dissemination was found in the liver, intra-abdominal lymph nodes, adrenal glands, stomach, kidney, central nervous system, spleen, superficial lymph nodes, small intestine and pancreas.
From these findings, we proposed the term pyothorax-associated lymphoma (PAL). PAL is a non-Hodgkin's lymphoma of exclusively B cell phenotype developing in the pleural cavity of patients with a Ͼ20 year history of chronic pyothorax. After our studies, in 1993, the association of PAL with EBV was reported. 3 However, the role of EBV infection in the development of PAL was still unclear.
In this study, we presented a PAL case in which change of the EBV clone in lymphoma cells was observed after antineoplastic chemotherapy. There are several reports concerning the clonality of the EBV genome in different specimens from the same patient with EBV-positive lymphoma, 10, 15, 24 mostly analyzing specimens from different sites at the same time. 15, 24 The chronological analysis of change of the EBV clone in lymphoma cells, ie comparison between the primary and recur- (c) One g of DNA was amplified by PCR, electrophoresed in 2% agarose gels, Southern blotted, and hybridized with non-radiolabeled EBNA2A-or EBNA2B-specific oligonucleotide probe. Signals were generated by chemiluminescence. One minute exposure at room temperature. EBNA2 sequences amplified by PCR in biopsy specimens and OPL-1 hybridize only with the EBNA2B-specific probe. Amplified EBNA2 products in Raji cells hybridize with the EBNA2A-specific probe. rent tumor is rare and only Barriga et al 10 reported change of the EBV clone in recurrent Burkitt's lymphoma. All of the previous reports deal with lymphomas developed in immunocompromised patients and there are no reports concerning the diversity of EBV clonality in EBV-positive lymphoma in clinically immunocompetent patients. In this aspect, this is the first report describing change of the EBV clone between the primary and recurrent lymphoma tissue.
The results in this study indicate that the different lymphoma at the level of clonality of the EBV genome and probably of IgH rearrangement developed after antineoplastic chemotherapy. Since most PAL cases show monoclonal nature at the level of the EBV genome, 3, 5 EBV containing cells in lymphoma tissue were derived from a single parent cell. However, as shown in Figure 1 , not all lymphoma cells expressed EBV latent infection genes. Even when we used the PCR-generated probes in BamHI-W region 25 for the primary tumor, approximately half of the lymphoma cells were positive for the presence of the EBV genome. 4 This suggests the loss of EBV genomes from a fraction of the tumor cells, and the possibility that EBV-infected cells had already undergone malignant transformation.
There is a possibility that EBV is just a passenger during the course of lymphomagenesis. In our case of PAL, a different clone of EBV might infect the surviving cells after antineoplastic chemotherapy and this clone might become predominant. However, we could not show the productive infection of EBV in lymphoma tissue although the patient showed the higher anti-VCA IgG in his serum at first biopsy. We also tried Southern blot analysis for the clonality of EBV using the LMP2 oligonucleotide probe, however, multiple restriction enzyme fragments were not found, denying productive infection of EBV (results not shown). Furthermore, Southern blot analysis for IgH rearrangement revealed clear rearranged bands in the recurrent tumor. In the primary tumor, any clear bands are not detected, probably due to the heteroploid pattern of its chromosomes or possibly polyclonal nature in the IgH gene. These findings suggest that the recurrent tumor is different as a whole from the primary one also in the IgH rearrangement although the recurrent clone might have existed in the primary tumor as a minor population. Even when EBV may infect the already transformed B cells, the infection must occur at a relatively early phase of lymphomagenesis.
When considering the long duration of chronic pyothorax before the onset of PALs, the most likely scenario for the development of PAL would be as follows: The long-standing inflammamtory stimuli might induce genetic aberrations in pre-neoplastic B cells. EBV infection of B cells might cause advantages in the accumulation of genetic lesions through its immortalizing effects on B cells. Therefore, in the early phase of lymphomagenesis, there would be multiple neoplastic B cell clones infected with different EBV clones. In the course of progression of the tumor, the particular clones would be selected and become predominant. This possible scenario might suggest the poly-or oligo-clonal origin of PAL. Thus, there might be several minor clones at the level of the EBV genome in the primary tumor. These clones might be neoplastic lymphoma cells or EBV-transformed B cells undergoing some pre-neoplastic changes, ie the cells situated between lymphoblastoid cells and overt lymphoma. The resistant clones to chemotherapy among them may develop into another overt lymphoma.
We suggest a poly-or oligoclonal origin of PAL. Although most PAL cases are monoclonal at the level of EBV genome, 3, 5 the detection of minor clones might be difficult in Southern blot analysis for TR of EBV. Poly-or oligoclonality of the EBV genome suggests the underlying immunosuppressive conditions in the development of PAL. 15 Since systemic immunosuppressive condition has not been noted in PAL patients, local immunosuppressive circumstances induced by some inflammatory cytokines, such as interleukin-10 may be involved, as we showed in a PAL-derived cell line. 16 Furthermore, HLA allotypes and some mutations in EBV latent infection genes might affect efficient killing of EBV-positive cells by host CTLs. Change of the EBV clone in this PAL case has produced many suggestions in the analysis of the mechanism of development of PAL.
